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Previewsdefective SNARE complex assembly and
neurodegeneration (Sharma et al., 2011).
It is thus conceivable that reactive interme-
diates produced during the SNARE cycle
could induce a general age-dependent
neurotoxicity (Mattson, 2003). Hsc70/Sgt
form a trimeric complex with the synaptic
vesicle-associated co-chaperone cysteine
string protein a (Tobaben et al., 2001), and
this complexuses thechaperoneactivityof
Hsc70 to refold fusion incompetent SNAP-
25 conformers (Sharma et al., 2011).
Intriguingly, both Hsc70 and Sgt are upre-
gulated with enhanced synaptic activity
(Sharma et al., 2011). It is thus conceivable
that changes in the relative levels of the two
proteins in response to specific patterns of
synaptic activity switch Hsc70 between its
refolding chaperone function and its endo-
somal microautophagy function. As such,
Hsc70 would switch from trying to refold
SNAP-25 to targeting the protein, which
has two microautophagy recognition mo-
tifs, to endosomal microautophagy.
Moreover, Uytterhoeven et al. (2015)
find that ATP prevents oligomerization
and the membrane deformation proper-
ties of Hsc70. Thus, in the presence ofabundant ATP, Hsc70 would function as
a chaperone but, with ATP deficiency, it
would switch to a protein degradation
mode. Remarkably, despite the fact that
ATP synthesis is driven locally in the syn-
apse and there is a large reservoir of ATP,
the incredible metabolic demands of the
synapse means that even brief interrup-
tion in activity-stimulated ATP synthesis
impairs presynaptic function (Rangaraju
et al., 2014). Thus, a simple switch in
the local availability of ATP could provide
an attractive mechanism to balance re-
folding versus degradation of synaptic
proteins.
It is likely that synaptic endosomal mi-
croautophagy is but one of many pro-
cesses that will be discovered to function
in the local environment of the synapse to
ensure the controlled activity of this key
functional unit of the nervous system.REFERENCES
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In this issue ofNeuron, Shen et al. (2015) demonstrate that theM4muscarinic receptor regulates striatal plas-
ticity. The authors use an M4-positive allosteric modulator, which facilitates long-term depression in direct
pathway neurons and reverses aberrant plasticity in levodopa-induced dyskinesia.The basal ganglia’s function in decision-
making and action selection depends on
robust plasticity, driven by sensory expe-
rience and feedback about action out-
comes. Flexible behavior requires bidi-
rectional plasticity: both potentiation and
depotentiation (or depression) of synapticstrengths, which has been studied exten-
sively in the input nucleus of the basal
ganglia, the striatum. A fundamental un-
answered question, however, is how cor-
ticostriatal long-term depression (LTD)
occurs in striatal direct pathway neurons.
While the mechanisms governing indirectpathway LTD have been studied exten-
sively, delineating a parallel mechanism
in direct pathway neurons has proved
more difficult. In this issue of Neuron,
Shen et al. (2015) close the gap in our
knowledge of direct pathway LTD by
demonstrating that type 4 muscarinicovember 18, 2015 ª2015 Elsevier Inc. 621
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Figure 1. Parallel Pathways for Striatal Synaptic Plasticity
Major synaptic inputs (top) to striatal projection neurons (direct pathway, dSPNs; indirect pathway, iSPNs,
bottom) are pictured. Key receptors and signaling molecules involved in synaptic plasticity are shown.
Abbreviations: D2, dopamine type 2-like receptor; D1, dopamine type 1-like receptor; M2,3,4, muscarinic
type 2,3,4 receptors; A2A, adenosine 2A receptor; cAMP (cyclic adenosine monophosphate).
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Previewsreceptor (M4R) activation facilitates
direct pathway LTD. The authors apply
this discovery to a neurological condi-
tion thought to arise from aberrant syn-
aptic plasticity, levodopa-induced dyski-
nesia. This common complication of
dopamine replacement therapy was
reduced in two animal models of Parkin-
son’s disease treated with an M4R posi-
tive allosteric modulator, uncovering a
potential therapeutic target. Their find-
ings support a long-hypothesized mech-
anism for direct pathway LTD and
demonstrate the M4Rs may indeed be
the missing link.
The basal ganglia are crucial for
learning, using past experience to guide
future decisions, which in turn affect
motor planning and cognition (Yin and
Knowlton, 2006). How is basal ganglia-
dependent behavior shaped at the cellular
level? Evidence supports bidirectional
synaptic plasticity of excitatory inputs
onto striatal principal neurons, or spiny
projection neurons (SPNs), as critical
both in learning and disease states (Kreit-
zer andMalenka, 2007; Yin and Knowlton,
2006). Rewarding outcomes regulate this
plasticity through dopamine and other
neuromodulators. SPNs receive glutama-
tergic inputs from the cortex and thal-
amus, local GABAergic and cholinergic
inputs, and neuromodulatory input, in-
cluding dopaminergic input from the
midbrain (see Figure 1). SPNs can be sub-622 Neuron 88, November 18, 2015 ª2015 Edivided into two intermingled groups,
direct pathway neurons (dSPNs, which
project directly to basal ganglia output)
and indirect pathway neurons (iSPNs,
which project via several synapses to
basal ganglia output). Complementary
sets of inhibitory and excitatory G pro-
tein-coupled receptors on SPNs are
believed to regulate SPN long-term
potentiation (LTP) and LTD. Direct
pathway SPNs selectively express Gs-
coupled dopamine type-1 receptors
(D1R) and Gi/o-coupled type-4 muscarinic
receptors (M4R). Conversely, indirect
pathway SPNs selectively express Gi/o-
coupled dopamine type 2 receptor (D2R)
and Gs-coupled adenosine A2A receptors
(A2AR). Gi/o and Gs pathways bidirec-
tionally modulate downstream signaling,
including cAMP, regulator of G protein
signaling type 4 (RGS4), and endocanna-
binoid release to control plasticity (Cala-
bresi et al., 2000; Kreitzer and Malenka,
2007; Lerner and Kreitzer, 2012). Neuro-
modulators like dopamine, adenosine,
and acetylcholine bias SPNs to LTP or
LTD. Specifically, indirect pathway LTD
depends on dopamine and D2R activa-
tion, as established by several groups
(Calabresi et al., 1992; Kreitzer and Mal-
enka, 2007; Shen et al., 2008).
How is direct pathway LTD regulated?
The Gi/o-coupled M4R, located on
dSPNs, has long been suspected based
on its analogous intracellular signaling.lsevier Inc.M4R could act as a direct pathway analog
of D2R, favoring LTD, whereas D1R could
function in parallel to A2AR, favoring LTP.
Like other striatal cholinergic receptors,
M4R activation depends on local acetyl-
choline release by tonically active cholin-
ergic interneurons. Multiple cholinergic
receptor subtypes are expressed on
many striatal cell types (see Figure 1),
leading to a multiplicity of effects. Testing
the role of M4R has been experimentally
challenging for three primary reasons:
(1) a lack of specificM4R agonists and an-
tagonists; (2) cholinergic receptors on
both pre- and postsynaptic elements, on
almost every striatal cell type; and (3) the
technical difficulty of inducing bidirec-
tional synaptic plasticity with physiologi-
cally meaningful protocols in the slice
preparation. Many plasticity protocols
drive dopamine release (e.g., through
local electrical stimulation); they may
bias in favor of dSPN LTP and iSPN
LTD, making it difficult to study dSPN
LTD or iSPN LTP. Despite experimental
limitations, several research groups have
attempted to study M4Rs in healthy ro-
dents and disease models (Gomeza
et al., 1999; Martella et al., 2009). These
findings, however, have not specifically
addressed M4R in direct pathway LTD.
The development of highly selective M4
positive allosteric modulators (PAMs)
(Shirey et al., 2008) is one promising
approach. M4R PAMs do not activate
the receptor directly, but interact with an
allosteric site to increase affinity and
coupling efficiency to G proteins (Shirey
et al., 2008). Shen et al. (2015) used
several novel M4R PAMs to identify how
M4R signaling regulates striatal plasticity
and levodopa-induced dyskinesia. This
work builds on the group’s prior work
showing that dSPN spike timing-depen-
dent plasticity (STDP) LTD could be
induced in the presence of a D1R antago-
nist (Shen et al., 2008). However, Shen
et al. (2015) combine STDP with pharma-
cology to show that M4R activation alone
can facilitate LTD in dSPNs and reverse
aberrant plasticity associated with levo-
dopa-induced dyskinesia.
Several experiments by Shen et al.
(2015) demonstrate that endogenous
cholinergic signaling promotes direct
pathway LTD. First, in ex vivo perforated
patch recordings, they show the combi-
nation of the M4R PAM and a negative
Neuron
Previewstiming STDP protocol induces direct
pathway LTD, even without blocking
D1R. Second, they show postsynaptic
dSPN M4R (not M4R on other cells) are
necessary for LTD; direct pathway LTD
could not be induced in mice with cell-
type-specific deletion of M4R in dSPNs,
nor could it be restored with M4R PAM
application. Third, when the authors
artificially elevated cholinergic inter-
neuron activity by cell-type-specific acti-
vation with the hM3D(q) DREADD, the
same negative timing STDP led to robust
direct pathway LTD. The authors went
on to dissect downstream signaling,
demonstrating that, like indirect pathway
LTD, direct pathway LTD depends on
RGS4 and endocannabinoids (Gerdeman
et al., 2002; Lerner and Kreitzer, 2012),
confirming a closely parallel process.
These findings provide support for the
long-hypothesized role of the M4R in
striatal plasticity, but also have behavioral
consequences. Levodopa-induced dyski-
nesia is a common complication of long-
term dopamine replacement therapy in
Parkinson’s disease. In this condition,
therapeutic doses of the dopamine
precursor levodopa trigger disabling
involuntary movements. Presently, few
therapeutic strategies exist to treat levo-
dopa-induced dyskinesia. While the in-
duction and expression mechanisms of
levodopa-induced dyskinesia are still
unknown, many hypothesize that dysre-
gulated striatal dopamine and aberrant
corticostriatal direct pathway plasticity
contribute (Cenci and Konradi, 2010).
Key evidence supporting this hypothesis
includes alterations in glutamatergic syn-
aptic function (Bagetta et al., 2012; Fieb-
linger et al., 2014) and loss of depotentia-
tion in ex vivo slices from dyskinetic
animals (Picconi et al., 2003). In vivo,
excess direct pathway LTP may promote
higher direct pathway activity during
levodopa exposure, leading to invol-
untary movements. Preventing or re-
versing this aberrant plasticity might
permit longer and more effective use of
dopamine replacement therapy in Parkin-
son’s disease.
To test the role of M4Rs in synaptic de-
potentiation, the authors used the M4RPAM in mice with levodopa-induced
dyskinesia, produced by combining a
common rodent model of parkinsonism
with repeated levodopa treatment. To
assess changes in striatal plasticity, they
again used STDP, but used a positive
timing protocol to trigger LTP. Consistent
with prior findings, dSPN LTP was
induced in levodopa-treated (dyskinetic)
animals, whereas LTP could not be
induced in untreated (parkinsonian) ani-
mals. Furthermore, the M4R PAM
reversed the aberrant LTP associated
with levodopa treatment. The authors
tested whether this drug reduces levo-
dopa-induced dyskinesia in vivo, admin-
istering levodopa and the M4R PAM to
parkinsonian mice and non-human pri-
mates. Impressively, the M4R PAM less-
ened levodopa-induced dyskinesia in
both models, and to a degree similar
to an existing drug therapy, amanta-
dine. This result implies that restoration
of dSPN LTD/depotentiation can re-
duce levodopa-induced dyskinesia, and
opens up additional areas of drug
development.
While the results from this study expand
our knowledge of M4R signaling and
striatal plasticity, several questions
remain. While the authors showed that
dSPN M4R signaling was required to
regulate LTD in vitro, in vivo the M4R
PAM was given systemically; it may have
multiple sites of action. Systemic adminis-
tration is obviously more clinically viable,
but to mechanistically connect M4Rs
in direct pathway neurons, LTD, and a
reduction in levodopa-induced dyski-
nesia, additional experiments would be
required. M4R located on other cell types,
including striatal cholinergic interneurons,
may regulate plasticity; cell-type-specific
modulation would help clarify this mecha-
nism in vivo.
A major limitation of many candidate
dyskinesia treatments is their predilection
to reduce levodopa’s therapeutic effi-
cacy. For example, drugs which reduce
dopamine release might reduce dyski-
nesia, but at the expense of antiparkinso-
nian benefit. The authors show some
preliminary evidence that the therapeutic
benefits of levodopa are not significantlyNeuron 88, Naltered with an M4R PAM, but this will
need to be replicated in larger groups of
animals with a wider range of doses.
However, these findings represent a ma-
jor contribution to our understanding of
striatal plasticity, and are an impressive
start in unraveling the clinical role of M4
PAMs in treatment of levodopa-induced
dyskinesia.
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